Arrhythmogenic right ventricular cardiomyopathy (ARVC), also known as arrhythmogenic right ventricular dysplasia, is characterized by arrhythmias originating from the right ventricle and specific pathological changes in the right ventricle. It is a significant cause of sudden cardiac death in young adults. The life expectancy of patients with ARVC cannot be determined, but there are measures available that can reduce the likelihood of sudden death. In the early stages, the symptoms of these patients are non-specific, such as palpitations, fainting, chest pain, and shortness of breath. These atypical symptoms may persist for decades and often go unnoticed due to their lack of specificity, leading to delayed diagnosis. If a patient's electrocardiogram shows left bundle branch block, frequent premature ventricular contractions, or ventricular tachycardia, but no cardiac abnormalities are found in general examinations, or if there is right ventricular hypertrophy, the possibility of ARVC should be considered. Cardiac magnetic resonance imaging (MRI) is crucial in the diagnosis of ARVC, as it can reveal specific changes. The treatment of ARVC primarily focuses on controlling arrhythmias and preventing sudden death. Beta-blockers and the implantation of an implantable cardioverter-defibrillator (ICD) can provide some efficacy.